Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures
For successful clinical tumor immunotherapy outcomes, strong immune responses against tumor antigens must be generated. Cell-based vaccines compromise one strategy with which to induce appropriate strong immune responses. Previously, we established a natural killer T-cell (NKT) ligand-loaded, adenov...
Gespeichert in:
| Veröffentlicht in: | Gene therapy 2014-01, Vol.21 (1), p.106-114 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | 1 |
| container_start_page | 106 |
| container_title | Gene therapy |
| container_volume | 21 |
| creator | Kim, E-K Seo, H-S Chae, M-J Jeon, I-S Song, B-Y Park, Y-J Ahn, H M Yun, C-O Kang, C-Y |
| description | For successful clinical tumor immunotherapy outcomes, strong immune responses against tumor antigens must be generated. Cell-based vaccines compromise one strategy with which to induce appropriate strong immune responses. Previously, we established a natural killer T-cell (NKT) ligand-loaded, adenoviral vector-transduced B-cell-based anticancer cellular vaccine. To enhance tumor antigen delivery to B cells, we established a modified adenoviral vector (Ad-k35) that encoded a truncated form of the breast cancer antigen Her2/
neu
(Ad-k35HM) in which fiber structure was substituted with adenovirus serotype 35. We observed increased tumor antigen expression with Ad-k35HM in both human and murine B cells. In addition, an Ad-k35HM-transduced B-cell vaccine elicited strong antigen-specific cellular and humoral immune responses that were further enhanced with the additional loading of soluble NKT ligand KBC009. An Ad-k35HM-transduced, KBC009-loaded B-cell vaccine efficiently suppressed the
in vivo
growth of established tumors in a mouse model. Moreover, the vaccine elicited human leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in B6.Cg (CB)-Tg (HLA-A/H2-D) 2Enge/Jat mice. These findings indicated that the Ad-k35 could be appropriate for the preclinical and clinical development of B-cell-based anticancer immunotherapies. |
| doi_str_mv | 10.1038/gt.2013.65 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492630626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A357759726</galeid><sourcerecordid>A357759726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c552t-4f831f26c5b410353f3c668578676b3bf440bc2cea707ce4b56538fa3e4d024b3</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoso7jh64w-QgCB-0DHNZ3u5LqsuLAh-XJc0PelkaZMxSVf3b_iLTZ1Vd9QLKaSQPOcJ580piocV3lSY1i-HtCG4ohvBbxWriklRcibI7WKFG9GUsiL1UXEvxguMMZM1uVscEUYIF7RZFd9O3VY5DT1SLtk0Tz4gO02z82kLQe1gTlYjMAZ0Qt6gV6WGcSw7FXPJpdLaOkApKBf7ebF8sWmLJt9bYxdnD85f2qBGdJkF2a29S8o66waUrnaAKEfGdhBQTGHWaQ4Q7xd3jBojPLj-r4tPr08_nrwtz9-9OTs5Pi815ySVzNS0MkRo3rEcA6eGaiFqLmshRUc7wxjuNNGgJJYaWMcFp7VRFFiPCevouni69-6C_zxDTO1k49KdcuDn2FasIYJikZf_QLEklNY4o4__QC_8HFxuJFOS1qKpKvabGtQIrXXG5wz1Im2PKZeSN_LHtZt_UPnrYbI5STA27x8UPDsoWNKGr2lQc4zt2Yf3h-yTG-wW1Ji20Y_5vb2Lh-DzPaiDjzGAaXfBTipctRVulwFsh9QuA9jmgNfFo-v2526C_hf6c-Iy8GIPxHzkBgg38vlb9x3uqOJW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1473869114</pqid></control><display><type>article</type><title>Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Kim, E-K ; Seo, H-S ; Chae, M-J ; Jeon, I-S ; Song, B-Y ; Park, Y-J ; Ahn, H M ; Yun, C-O ; Kang, C-Y</creator><creatorcontrib>Kim, E-K ; Seo, H-S ; Chae, M-J ; Jeon, I-S ; Song, B-Y ; Park, Y-J ; Ahn, H M ; Yun, C-O ; Kang, C-Y</creatorcontrib><description>For successful clinical tumor immunotherapy outcomes, strong immune responses against tumor antigens must be generated. Cell-based vaccines compromise one strategy with which to induce appropriate strong immune responses. Previously, we established a natural killer T-cell (NKT) ligand-loaded, adenoviral vector-transduced B-cell-based anticancer cellular vaccine. To enhance tumor antigen delivery to B cells, we established a modified adenoviral vector (Ad-k35) that encoded a truncated form of the breast cancer antigen Her2/
neu
(Ad-k35HM) in which fiber structure was substituted with adenovirus serotype 35. We observed increased tumor antigen expression with Ad-k35HM in both human and murine B cells. In addition, an Ad-k35HM-transduced B-cell vaccine elicited strong antigen-specific cellular and humoral immune responses that were further enhanced with the additional loading of soluble NKT ligand KBC009. An Ad-k35HM-transduced, KBC009-loaded B-cell vaccine efficiently suppressed the
in vivo
growth of established tumors in a mouse model. Moreover, the vaccine elicited human leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in B6.Cg (CB)-Tg (HLA-A/H2-D) 2Enge/Jat mice. These findings indicated that the Ad-k35 could be appropriate for the preclinical and clinical development of B-cell-based anticancer immunotherapies.</description><identifier>ISSN: 0969-7128</identifier><identifier>EISSN: 1476-5462</identifier><identifier>DOI: 10.1038/gt.2013.65</identifier><identifier>PMID: 24225639</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/24/590/2292 ; 631/326/596/2561 ; 692/699/67/1059/2325 ; Adenovirus ; Animals ; Antigens ; B-Lymphocytes - immunology ; B-Lymphocytes - virology ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Vaccines - immunology ; Cell Biology ; Cells, Cultured ; Dependovirus - genetics ; Dependovirus - metabolism ; Female ; Gene Expression ; Gene Therapy ; Genetic Vectors ; HLA-A2 Antigen - immunology ; Human Genetics ; Humans ; Identification and classification ; Immunotherapy ; Mammary Neoplasms, Experimental - immunology ; Mammary Neoplasms, Experimental - therapy ; Mice ; Mice, Inbred BALB C ; Nanotechnology ; Natural Killer T-Cells - immunology ; Oncology, Experimental ; original-article ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; T-Lymphocytes, Cytotoxic - immunology ; Testing ; Tumor antigens ; Tumors ; Vaccines ; Xenograft Model Antitumor Assays</subject><ispartof>Gene therapy, 2014-01, Vol.21 (1), p.106-114</ispartof><rights>Macmillan Publishers Limited 2014</rights><rights>COPYRIGHT 2014 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c552t-4f831f26c5b410353f3c668578676b3bf440bc2cea707ce4b56538fa3e4d024b3</citedby><cites>FETCH-LOGICAL-c552t-4f831f26c5b410353f3c668578676b3bf440bc2cea707ce4b56538fa3e4d024b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24225639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, E-K</creatorcontrib><creatorcontrib>Seo, H-S</creatorcontrib><creatorcontrib>Chae, M-J</creatorcontrib><creatorcontrib>Jeon, I-S</creatorcontrib><creatorcontrib>Song, B-Y</creatorcontrib><creatorcontrib>Park, Y-J</creatorcontrib><creatorcontrib>Ahn, H M</creatorcontrib><creatorcontrib>Yun, C-O</creatorcontrib><creatorcontrib>Kang, C-Y</creatorcontrib><title>Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures</title><title>Gene therapy</title><addtitle>Gene Ther</addtitle><addtitle>Gene Ther</addtitle><description>For successful clinical tumor immunotherapy outcomes, strong immune responses against tumor antigens must be generated. Cell-based vaccines compromise one strategy with which to induce appropriate strong immune responses. Previously, we established a natural killer T-cell (NKT) ligand-loaded, adenoviral vector-transduced B-cell-based anticancer cellular vaccine. To enhance tumor antigen delivery to B cells, we established a modified adenoviral vector (Ad-k35) that encoded a truncated form of the breast cancer antigen Her2/
neu
(Ad-k35HM) in which fiber structure was substituted with adenovirus serotype 35. We observed increased tumor antigen expression with Ad-k35HM in both human and murine B cells. In addition, an Ad-k35HM-transduced B-cell vaccine elicited strong antigen-specific cellular and humoral immune responses that were further enhanced with the additional loading of soluble NKT ligand KBC009. An Ad-k35HM-transduced, KBC009-loaded B-cell vaccine efficiently suppressed the
in vivo
growth of established tumors in a mouse model. Moreover, the vaccine elicited human leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in B6.Cg (CB)-Tg (HLA-A/H2-D) 2Enge/Jat mice. These findings indicated that the Ad-k35 could be appropriate for the preclinical and clinical development of B-cell-based anticancer immunotherapies.</description><subject>631/250/24/590/2292</subject><subject>631/326/596/2561</subject><subject>692/699/67/1059/2325</subject><subject>Adenovirus</subject><subject>Animals</subject><subject>Antigens</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - virology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Vaccines - immunology</subject><subject>Cell Biology</subject><subject>Cells, Cultured</subject><subject>Dependovirus - genetics</subject><subject>Dependovirus - metabolism</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>Genetic Vectors</subject><subject>HLA-A2 Antigen - immunology</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Immunotherapy</subject><subject>Mammary Neoplasms, Experimental - immunology</subject><subject>Mammary Neoplasms, Experimental - therapy</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Nanotechnology</subject><subject>Natural Killer T-Cells - immunology</subject><subject>Oncology, Experimental</subject><subject>original-article</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Testing</subject><subject>Tumor antigens</subject><subject>Tumors</subject><subject>Vaccines</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0969-7128</issn><issn>1476-5462</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkl2L1DAUhoso7jh64w-QgCB-0DHNZ3u5LqsuLAh-XJc0PelkaZMxSVf3b_iLTZ1Vd9QLKaSQPOcJ580piocV3lSY1i-HtCG4ohvBbxWriklRcibI7WKFG9GUsiL1UXEvxguMMZM1uVscEUYIF7RZFd9O3VY5DT1SLtk0Tz4gO02z82kLQe1gTlYjMAZ0Qt6gV6WGcSw7FXPJpdLaOkApKBf7ebF8sWmLJt9bYxdnD85f2qBGdJkF2a29S8o66waUrnaAKEfGdhBQTGHWaQ4Q7xd3jBojPLj-r4tPr08_nrwtz9-9OTs5Pi815ySVzNS0MkRo3rEcA6eGaiFqLmshRUc7wxjuNNGgJJYaWMcFp7VRFFiPCevouni69-6C_zxDTO1k49KdcuDn2FasIYJikZf_QLEklNY4o4__QC_8HFxuJFOS1qKpKvabGtQIrXXG5wz1Im2PKZeSN_LHtZt_UPnrYbI5STA27x8UPDsoWNKGr2lQc4zt2Yf3h-yTG-wW1Ji20Y_5vb2Lh-DzPaiDjzGAaXfBTipctRVulwFsh9QuA9jmgNfFo-v2526C_hf6c-Iy8GIPxHzkBgg38vlb9x3uqOJW</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Kim, E-K</creator><creator>Seo, H-S</creator><creator>Chae, M-J</creator><creator>Jeon, I-S</creator><creator>Song, B-Y</creator><creator>Park, Y-J</creator><creator>Ahn, H M</creator><creator>Yun, C-O</creator><creator>Kang, C-Y</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>7QO</scope><scope>7T5</scope></search><sort><creationdate>20140101</creationdate><title>Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures</title><author>Kim, E-K ; Seo, H-S ; Chae, M-J ; Jeon, I-S ; Song, B-Y ; Park, Y-J ; Ahn, H M ; Yun, C-O ; Kang, C-Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c552t-4f831f26c5b410353f3c668578676b3bf440bc2cea707ce4b56538fa3e4d024b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>631/250/24/590/2292</topic><topic>631/326/596/2561</topic><topic>692/699/67/1059/2325</topic><topic>Adenovirus</topic><topic>Animals</topic><topic>Antigens</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - virology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Vaccines - immunology</topic><topic>Cell Biology</topic><topic>Cells, Cultured</topic><topic>Dependovirus - genetics</topic><topic>Dependovirus - metabolism</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>Genetic Vectors</topic><topic>HLA-A2 Antigen - immunology</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Immunotherapy</topic><topic>Mammary Neoplasms, Experimental - immunology</topic><topic>Mammary Neoplasms, Experimental - therapy</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Nanotechnology</topic><topic>Natural Killer T-Cells - immunology</topic><topic>Oncology, Experimental</topic><topic>original-article</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Testing</topic><topic>Tumor antigens</topic><topic>Tumors</topic><topic>Vaccines</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, E-K</creatorcontrib><creatorcontrib>Seo, H-S</creatorcontrib><creatorcontrib>Chae, M-J</creatorcontrib><creatorcontrib>Jeon, I-S</creatorcontrib><creatorcontrib>Song, B-Y</creatorcontrib><creatorcontrib>Park, Y-J</creatorcontrib><creatorcontrib>Ahn, H M</creatorcontrib><creatorcontrib>Yun, C-O</creatorcontrib><creatorcontrib>Kang, C-Y</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>Proquest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><jtitle>Gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, E-K</au><au>Seo, H-S</au><au>Chae, M-J</au><au>Jeon, I-S</au><au>Song, B-Y</au><au>Park, Y-J</au><au>Ahn, H M</au><au>Yun, C-O</au><au>Kang, C-Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures</atitle><jtitle>Gene therapy</jtitle><stitle>Gene Ther</stitle><addtitle>Gene Ther</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>21</volume><issue>1</issue><spage>106</spage><epage>114</epage><pages>106-114</pages><issn>0969-7128</issn><eissn>1476-5462</eissn><abstract>For successful clinical tumor immunotherapy outcomes, strong immune responses against tumor antigens must be generated. Cell-based vaccines compromise one strategy with which to induce appropriate strong immune responses. Previously, we established a natural killer T-cell (NKT) ligand-loaded, adenoviral vector-transduced B-cell-based anticancer cellular vaccine. To enhance tumor antigen delivery to B cells, we established a modified adenoviral vector (Ad-k35) that encoded a truncated form of the breast cancer antigen Her2/
neu
(Ad-k35HM) in which fiber structure was substituted with adenovirus serotype 35. We observed increased tumor antigen expression with Ad-k35HM in both human and murine B cells. In addition, an Ad-k35HM-transduced B-cell vaccine elicited strong antigen-specific cellular and humoral immune responses that were further enhanced with the additional loading of soluble NKT ligand KBC009. An Ad-k35HM-transduced, KBC009-loaded B-cell vaccine efficiently suppressed the
in vivo
growth of established tumors in a mouse model. Moreover, the vaccine elicited human leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in B6.Cg (CB)-Tg (HLA-A/H2-D) 2Enge/Jat mice. These findings indicated that the Ad-k35 could be appropriate for the preclinical and clinical development of B-cell-based anticancer immunotherapies.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>24225639</pmid><doi>10.1038/gt.2013.65</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0969-7128 |
| ispartof | Gene therapy, 2014-01, Vol.21 (1), p.106-114 |
| issn | 0969-7128 1476-5462 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1492630626 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | 631/250/24/590/2292 631/326/596/2561 692/699/67/1059/2325 Adenovirus Animals Antigens B-Lymphocytes - immunology B-Lymphocytes - virology Biomedical and Life Sciences Biomedicine Cancer Cancer Vaccines - immunology Cell Biology Cells, Cultured Dependovirus - genetics Dependovirus - metabolism Female Gene Expression Gene Therapy Genetic Vectors HLA-A2 Antigen - immunology Human Genetics Humans Identification and classification Immunotherapy Mammary Neoplasms, Experimental - immunology Mammary Neoplasms, Experimental - therapy Mice Mice, Inbred BALB C Nanotechnology Natural Killer T-Cells - immunology Oncology, Experimental original-article Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism T-Lymphocytes, Cytotoxic - immunology Testing Tumor antigens Tumors Vaccines Xenograft Model Antitumor Assays |
| title | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T02%3A46%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20antitumor%20immunotherapeutic%20effect%20of%20B-cell-based%20vaccine%20transduced%20with%20modified%20adenoviral%20vector%20containing%20type%2035%20fiber%20structures&rft.jtitle=Gene%20therapy&rft.au=Kim,%20E-K&rft.date=2014-01-01&rft.volume=21&rft.issue=1&rft.spage=106&rft.epage=114&rft.pages=106-114&rft.issn=0969-7128&rft.eissn=1476-5462&rft_id=info:doi/10.1038/gt.2013.65&rft_dat=%3Cgale_proqu%3EA357759726%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1473869114&rft_id=info:pmid/24225639&rft_galeid=A357759726&rfr_iscdi=true |